You are here : Home > News Archive > CARBOGEN AMCIS Joins the Analges...
CARBOGEN AMCIS Joins the Analgesia Partnership Cluster

Multidisciplinary Venture to Foster Scientific Innovation in Pain Management

30 July 2012

BUBENDORF, Switzerland (July 30, 2012) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has joint the cluster of excellence Analgesia Partnership.


The Analgesia Partnership cluster promotes the collaboration among academia and established industry leaders involved in the discovery and the chemical/clinical development of new innovative analgesic drugs. Founded in 2008, the cluster counts as members several academic structures and private companies and has developed strong contacts with clinic departments at university hospitals.


As a new member, CARBOGEN AMCIS will bring to the cluster of excellence a long-standing expertise in the development of aseptic drugs (both small and large molecules) backed up by in-house pre-formulation, formulation and manufacturing capabilities. As part of the platform of services of Analgesia Partnership, CARBOGEN AMCIS will provide additional core competences such as (1) the formulation of new drug products, (2) the development of lyophilization cycles and (3) the fast supply of batches for pre-clinical and clinical studies.


“We are delighted to be part of the Analgesia Partnership cluster and to provide our competences to this one of a kind platform in pain innovation.” commented Maxime Laugier, Pharm.D., Pharmaceutical Development and Projects Director CARBOGEN AMCIS SAS “We are looking forward to contributing to the future achievements of the cluster in the field of pain management by sharing our expertise in the development and cGMP manufacturing of active pharmaceutical ingredients and drug products.”


In addition to its expertise in drug products development, CARBOGEN AMCIS brings to the Analgesia Partnership cluster leading process research and analytical services for the development of drug substances. With 70 multipurpose reactors ranging from 6 L up to 4’500 L, more than 120 analytical instruments such as NMR, HPLC, MS, GC and over 170 GLP fume hoods, CARBOGEN AMCIS can support the development and fast supply of drug substances.




CARBOGEN AMCIS AG ( is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.


Analgesia Partnership ( Analgesia Partnership was founded in 2008 as a result of the outstanding dynamism of academics and businesses bringing together their complementary cultures to design a Platform of Integrated Services focused on Pain Profiling.

Dishman Group ( is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.

16 February 2018
CARBOGEN AMCIS Announces a Successful Swissmedic Inspection of its Site in Vionnaz, Switzerland

11 October 2017
CARBOGEN AMCIS Announces a Successful FDA Inspection of its Headquarters Site in Bubendorf, Switzerland

21 July 2017
CARBOGEN AMCIS Sites at Bubendorf, Aarau and Neuland in Switzerland Successfully Pass Swissmedic Inspection

DCAT week

World ADC Berlin